**5. References**


ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene *23*, 5853-5857.


Alves, R.C., Alves, D., Guz, B., Matos, C., Viana, M., Harriz, M., Terrabuio, D., Kondo, M.,

Ansari, J., Palmer, D.H., Rea, D.W., and Hussain, S.A. (2009). Role of tyrosine kinase

Anzola, M. (2004). Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses

Apte, U., Zeng, G., Muller, P., Tan, X., Micsenyi, A., Cieply, B., Dai, C., Liu, Y., Kaestner,

Avruch, J., Khokhlatchev, A., Kyriakis, J.M., Luo, Z., Tzivion, G., Vavvas, D., and Zhang,

Balmanno, K., and Cook, S.J. (2009). Tumour cell survival signalling by the ERK1/2

Beenken, A., and Mohammadi, M. (2009). The FGF family: biology, pathophysiology and

Behari, J. (2010). The Wnt/beta-catenin signaling pathway in liver biology and disease.

Behari, J., Zeng, G., Otruba, W., Thompson, M.D., Muller, P., Micsenyi, A., Sekhon, S.S.,

Boyault, S., Rickman, D.S., de Reynies, A., Balabaud, C., Rebouissou, S., Jeannot, E., Herault,

Cariani, E., Lasserre, C., Seurin, D., Hamelin, B., Kemeny, F., Franco, D., Czech, M.P.,

Carmeliet, P., and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature *407*,

Chang, Q., Zhang, Y., Beezhold, K.J., Bhatia, D., Zhao, H., Chen, J., Castranova, V., Shi, X.,

Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease. Cell *127*, 469-

with survival and proliferation of hepatoma cells. J Hepatol *46*, 849-857. Bosch, F.X., Ribes, J., Diaz, M., and Cleries, R. (2004). Primary liver cancer: worldwide

Leoni, L., and Monga, S.P. (2007). R-Etodolac decreases beta-catenin levels along

A., Saric, J., Belghiti, J., Franco, D.*, et al.* (2007). Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology *45*, 42-52. Calvisi, D.F., Pinna, F., Meloni, F., Ladu, S., Pellegrino, R., Sini, M., Daino, L., Simile, M.M.,

De Miglio, M.R., Virdis, P.*, et al.* (2008). Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth

Ullrich, A., and Brechot, C. (1988). Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver

and Chen, F. (2009). Sustained JNK1 activation is associated with altered histone

inhibitors in lung cancer. Anticancer Agents Med Chem *9*, 569-575.

proteins in hepatocarcinogenesis. J Viral Hepat *11*, 383-393.

targeted molecular drugs. Ann Hepatol *10*, 21-27.

kinase cascade. Recent Prog Horm Res *56*, 127-155.

pathway. Cell Death Differ *16*, 368-377.

therapy. Nat Rev Drug Discov *8*, 235-253.

cirrhosis. Cancer Res *48*, 6844-6849.

249-257.

480.

Expert Rev Gastroenterol Hepatol *4*, 745-756.

incidence and trends. Gastroenterology *127*, S5-S16.

in human hepatocellular carcinoma. Cancer Res *68*, 4192-4200.

H3 methylations in human liver cancer. J Hepatol *50*, 323-333.

*23*, 5853-5857.

ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene

Gampel, O., and Polletti, P. (2011). Advanced hepatocellular carcinoma. Review of

K.H., and Monga, S.P. (2006). Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice. Hepatology *44*, 992-1002.

X.F. (2001). Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP


Giannelli, G., Mazzocca, A., Fransvea, E., Lahn, M., and Antonaci, S. (2011). Inhibiting TGFbeta signaling in hepatocellular carcinoma. Biochim Biophys Acta *1815*, 214-223. Giles, R.H., van Es, J.H., and Clevers, H. (2003). Caught up in a Wnt storm: Wnt signaling in

Gollob, J.A., Wilhelm, S., Carter, C., and Kelley, S.L. (2006). Role of Raf kinase in cancer:

Gordon, M.D., and Nusse, R. (2006). Wnt signaling: multiple pathways, multiple receptors,

Harada, N., Miyoshi, H., Murai, N., Oshima, H., Tamai, Y., Oshima, M., and Taketo, M.M.

Hawkins, M.J. (1995). Clinical trials of antiangiogenic agents. Curr Opin Oncol *7*, 90-93. Herbst, R.S. (2004). Review of epidermal growth factor receptor biology. Int J Radiat Oncol

Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K., Hasegawa,

Hsu, P.I., Chow, N.H., Lai, K.H., Yang, H.B., Chan, S.H., Lin, X.Z., Cheng, J.S., Huang, J.S.,

Hu, T.H., Huang, C.C., Lin, P.R., Chang, H.W., Ger, L.P., Lin, Y.W., Changchien, C.S., Lee,

Huang, X., Yang, C., Jin, C., Luo, Y., Wang, F., and McKeehan, W.L. (2009). Resident

Huang, X., Yu, C., Jin, C., Kobayashi, M., Bowles, C.A., Wang, F., and McKeehan, W.L.

Hui, L., Bakiri, L., Mairhorfer, A., Schweifer, N., Haslinger, C., Kenner, L., Komnenovic, V.,

Hui, L., Zatloukal, K., Scheuch, H., Stepniak, E., and Wagner, E.F. (2008). Proliferation of

growth factor-induced angiogenesis. Cancer Res *66*, 1481-1490.

and multiple transcription factors. J Biol Chem *281*, 22429-22433.

therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

(2002). Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res *62*, 1971-1977. Hassan, M.M., Curley, S.A., Li, D., Kaseb, A., Davila, M., Abdalla, E.K., Javle, M., Moghazy,

D.M., Lozano, R.D., Abbruzzese, J.L.*, et al.* (2010). Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer *116*, 1938-

G., Kishimoto, H., Iizuka, M.*, et al.* (2004). Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. The Journal of clinical

Ger, L.P., Huang, S.M.*, et al.* (1997). Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer

C.M., and Tai, M.H. (2003). Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer *97*, 1929-1940. Huang, C., Jacobson, K., and Schaller, M.D. (2004). MAP kinases and cell migration. J Cell

hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis.

(2006). Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial

Scheuch, H., Beug, H., and Wagner, E.F. (2007). p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet *39*,

human HCC cells and chemically induced mouse liver cancers requires JNK1-

cancer. Biochim Biophys Acta *1653*, 1-24.

Semin Oncol *33*, 392-406.

1946.

Biol Phys *59*, 21-26.

investigation *113*, 1774-1783.

research *17*, 2803-2809.

Sci *117*, 4619-4628.

741-749.

Molecular carcinogenesis *48*, 553-562.

dependent p21 downregulation. The Journal of clinical investigation *118*, 3943- 3953.


Lund, P., Schubert, D., Niketeghad, F., and Schirmacher, P. (2004). Autocrine inhibition of

Malumbres, M., and Barbacid, M. (2003). RAS oncogenes: the first 30 years. Nat Rev Cancer

Matsumoto, K., and Nakamura, T. (1996). Emerging multipotent aspects of hepatocyte

Mazzocca, A., Fransvea, E., Lavezzari, G., Antonaci, S., and Giannelli, G. (2009). Inhibition of

Min, L., He, B., and Hui, L. (2011). Mitogen-activated protein kinases in hepatocellular

Nelson, W.J., and Nusse, R. (2004). Convergence of Wnt, beta-catenin, and cadherin

Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G.D., Pham, T.A.,

Ornitz, D.M., and Itoh, N. (2001). Fibroblast growth factors. Genome biology *2*,

Ornitz, D.M., Xu, J., Colvin, J.S., McEwen, D.G., MacArthur, C.A., Coulier, F., Gao, G., and

Paez, J., and Sellers, W.R. (2003). PI3K/PTEN/AKT pathway. A critical mediator of

Pai, R., Dunlap, D., Qing, J., Mohtashemi, I., Hotzel, K., and French, D.M. (2008). Inhibition

Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA

Penn, L.J., Laufer, E.M., and Land, H. (1990). C-MYC: evidence for multiple regulatory

Petroulakis, E., Mamane, Y., Le Bacquer, O., Shahbazian, D., and Sonenberg, N. (2006).

Plotnikov, A.N., Schlessinger, J., Hubbard, S.R., and Mohammadi, M. (1999). Structural basis

Presta, M., Dell'Era, P., Mitola, S., Moroni, E., Ronca, R., and Rusnati, M. (2005). Fibroblast

for FGF receptor dimerization and activation. Cell *98*, 641-650.

growth through neo-angiogenesis regulation. Hepatology *50*, 1140-1151. McAuliffe, P.F., Meric-Bernstam, F., Mills, G.B., and Gonzalez-Angulo, A.M. (2010).

Cancer Lett *206*, 85-96.

growth factor. J Biochem *119*, 591-600.

pathways. Science *303*, 1483-1487.

pathogenesis. Clin Breast Cancer *10 Suppl 3*, S59-65.

carcinoma development. Semin Cancer Biol *21*, 10-20.

oncogenic signaling. Cancer Treat Res *115*, 145-167.

*3*, 459-465.

2307.

REVIEWS3005.

Biol Chem *271*, 15292-15297.

Cancer J Clin *55*, 74-108.

195-199.

signaling. Cancer Res *68*, 5086-5095.

functions. Semin Cancer Biol *1*, 69-80.

Growth Factor Rev *16*, 159-178.

chemotherapy response in human liver tumor cells by insulin-like growth factor-II.

transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma

Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and

Dillard-Telm, L., Tsai, S.P., Stephan, J.P.*, et al.* (2002). A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. The American journal of pathology *160*, 2295-

Goldfarb, M. (1996). Receptor specificity of the fibroblast growth factor family. J

of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin

mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer *94*,

growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine


Tovar, V., Alsinet, C., Villanueva, A., Hoshida, Y., Chiang, D.Y., Sole, M., Thung, S.,

Tsai, J.F., Chuang, L.Y., Jeng, J.E., Yang, M.L., Chang, W.Y., Hsieh, M.Y., Lin, Z.Y., and Tsai,

patients with hepatocellular carcinoma. Medicine (Baltimore) *76*, 213-226. Turner, N., and Grose, R. (2010). Fibroblast growth factor signalling: from development to

Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H., and Okamoto, E. (1997). Expression of

van der Meel, R., Symons, M.H., Kudernatsch, R., Kok, R.J., Schiffelers, R.M., Storm, G.,

Vanhaesebroeck, B., and Waterfield, M.D. (1999). Signaling by distinct classes of

Villanueva, A., Chiang, D.Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie,

Wang, W., Chen, J.X., Liao, R., Deng, Q., Zhou, J.J., Huang, S., and Sun, P. (2002). Sequential

Wang, Y., Macke, J.P., Abella, B.S., Andreasson, K., Worley, P., Gilbert, D.J., Copeland, N.G.,

Wehrli, M., Dougan, S.T., Caldwell, K., O'Keefe, L., Schwartz, S., Vaizel-Ohayon, D.,

Wong, C.M., Fan, S.T., and Ng, I.O. (2001). beta-Catenin mutation and overexpression in

Wu, A.L., Coulter, S., Liddle, C., Wong, A., Eastham-Anderson, J., French, D.M., Peterson,

Hepatol *52*, 550-559.

cancer. Nat Rev Cancer *10*, 116-129.

Discov Today *16*, 219-228.

hepatocellular carcinoma. Hepatology *25*, 619-623.

phosphoinositide 3-kinases. Exp Cell Res *253*, 239-254.

in cancer development. Nat Rev Cancer *9*, 537-549.

premature senescence. Mol Cell Biol *22*, 3389-3403.

frizzled. J Biol Chem *271*, 4468-4476.

5005.

136-145.

Moyano, S., Toffanin, S., Minguez, B.*, et al.* (2010). IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J

J.H. (1997). Clinical relevance of transforming growth factor-beta 1 in the urine of

hepatocyte growth factor and its receptor, the c-met proto-oncogene, in

Gallagher, W.M., and Byrne, A.T. (2011). The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. Drug

S., Minguez, B., Sole, M.*, et al.* (2008). Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology *135*, 1972-1983, 1983 e1971-1911. Wagner, E.F., and Nebreda, A.R. (2009). Signal integration by JNK and p38 MAPK pathways

activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced

Jenkins, N.A., and Nathans, J. (1996). A large family of putative transmembrane receptors homologous to the product of the Drosophila tissue polarity gene

Schejter, E., Tomlinson, A., and DiNardo, S. (2000). arrow encodes an LDLreceptor-related protein essential for Wingless signalling. Nature *407*, 527-530. Whittaker, S., Marais, R., and Zhu, A.X. (2010). The role of signaling pathways

in the development and treatment of hepatocellular carcinoma. Oncogene *29*, 4989-

hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer *92*,

A.S., and Sonoda, J. (2011). FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One *6*, e17868.


Zhu, A.X., Stuart, K., Blaszkowsky, L.S., Muzikansky, A., Reitberg, D.P., Clark, J.W., Enzinger, P.C., Bhargava, P., Meyerhardt, J.A., Horgan, K.*, et al.* (2007). Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer *110*, 581-589.
